Our observation that FAP+ and αSMA+ cells are distinct in GBM is in accord with our knowledge that CAFs in cancer are highly heterogenous in marker status and function [4, 9, 45], and suggests that mesenchymal stromal cells in the GBM tumor microenvironment are also heterogenous. The gene discussed is FAP; the disease is glioblastoma.